Sleep duration and risk of overall and 22 site‐specific cancers:a Mendelian randomization study by Titova, Olga et al.
                          Titova, O., Michaëlsson, K., Vithayathil, M., Mason, A., Mason, A. M.,
Kar, S., Burgess, S., & Larsson, S. C. (2020). Sleep duration and risk
of overall and 22 site‐specific cancers: a Mendelian randomization
study. International Journal of Cancer.
https://doi.org/10.1002/ijc.33286
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1002/ijc.33286
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Wiley at 10. Please
refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/user-guides/explore-bristol-research/ebr-terms/
C AN C E R E P I D EM I O LOG Y
Sleep duration and risk of overall and 22 site-specific cancers:
A Mendelian randomization study
Olga E. Titova1 | Karl Michaëlsson1 | Mathew Vithayathil2 | Amy M. Mason3,4 |
Siddhartha Kar5 | Stephen Burgess6,7 | Susanna C. Larsson1,8
1Unit of Medical Epidemiology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
2MRC Cancer Unit, University of Cambridge, Cambridge, UK
3British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
4National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge and Cambridge University Hospitals, Cambridge, UK
5MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, UK
6Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
7MRC Biostatistics Unit, University of Cambridge, Cambridge, UK
8Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Correspondence
Susanna C. Larsson, Department of Surgical
Sciences, The EpiHubben, Dag Hammarskjölds
väg 14 B, 75185 Uppsala, Sweden.
Email: susanna.larsson@surgsci.uu.se,
Funding information
Sir Henry Dale Fellowship jointly funded by the
Wellcome Trust and the Royal Society, Grant/
Award Number: 204623/Z/16/Z; Cancer
Research UK Programme Grant, Grant/Award
Number: C18281; EC-Innovative Medicines
Initiative (BigData@Heart); The Integrative
Cancer Epidemiology Programme, Grant/
Award Number: A19169; The National
Institute for Health Research; the Swedish
Research Council for Health, Working Life and
Welfare (Forte); Swedish Research Council for
Health, Working Life and Welfare
Abstract
Studies of sleep duration in relation to the risk of site-specific cancers other than
breast cancer are scarce. Furthermore, the available results are inconclusive and the
causality remains unclear. We aimed to investigate the potential causal associations
of sleep duration with overall and site-specific cancers using the Mendelian randomi-
zation (MR) design. Single-nucleotide polymorphisms associated with the sleep traits
identified from a genome-wide association study were used as instrumental variables
to estimate the association with overall cancer and 22 site-specific cancers among
367 586 UK Biobank participants. A replication analysis was performed using data
from the FinnGen consortium (up to 121 579 individuals). There was suggestive evi-
dence that genetic liability to short-sleep duration was associated with higher odds of
cancers of the stomach (odds ratio [OR], 2.22; 95% confidence interval [CI], 1.15-
4.30; P = .018), pancreas (OR, 2.18; 95% CI, 1.32-3.62; P = .002) and colorectum (OR,
1.48; 95% CI, 1.12-1.95; P = .006), but with lower odds of multiple myeloma (OR,
0.47; 95% CI, 0.22-0.99; P = .047). Suggestive evidence of association of genetic lia-
bility to long-sleep duration with lower odds of pancreatic cancer (OR, 0.44; 95% CI,
0.25-0.79; P = .005) and kidney cancer (OR, 0.44; 95% CI, 0.21-0.90; P = .025) was
observed. However, none of these associations passed the multiple comparison
threshold and two-sample MR analysis using FinnGen data did not confirm these
findings. In conclusion, this MR study does not provide strong evidence to support
Abbreviations: BMI, body mass index; CI, confidence interval; FDR, false discovery rate; GWAS, genome-wide association study; IGF, insulin-like growth factor; IVW, inverse variance-weighted;
MR, Mendelian randomization; OR, odds ratio; SNP, single-nucleotide polymorphism.
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causal associations of sleep duration with risk of overall and site-specific cancers. Fur-
ther MR studies are required.
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1 | INTRODUCTION
Sleep is essential for maintaining optimal physiological processes. Sleep-
related problems are becoming increasingly prevalent in modern society,
affecting 20% to 40% of the general population.1 During the last decade,
increased attention has been paid to understanding to what extent
impaired sleep patterns, including those characterized by habitual short-
sleep duration, are associated with various adverse health outcomes, such
as obesity, type 2 diabetes, cognitive impairment, cardiovascular disease
and all-cause mortality.2 Growing evidence suggests that short- and long-
sleep duration may also be implicated in the development of cancer.1,3,4
Several observational studies have examined the association
between short-sleep (commonly defined as <7 hours/night) and long
(commonly defined as ≥9 hours/night) sleep duration and cancer risk.3
An increased risk of colorectal, breast and lung cancers among short and
long sleepers5-7 and an increased risk of stomach cancer8 and overall
cancer among short sleepers9 have been reported by these observations.
For example, a study of 23 620 middle-aged participants adults found
that individuals who on average slept less than 6 hours had 43% higher
risk of cancer (846 cases during a mean follow-up of 7.8 years) com-
pared with those who slept 7 to <8 hours.9 The effect of sleep depriva-
tion on tumor development has also been investigated in experimental
studies in mice, and it has been shown that chronic sleep restriction
impairs antitumor immune responses and increases growth rate in pul-
monary metastasis.10 However, the results remain inconsistent as sev-
eral epidemiological studies and meta-analyses have found no
association between sleep duration and risk of cancer.3,11,12 Based on
available evidence, no clear consensus about the effect of sleep dura-
tion on cancer risk can be drawn as observational studies are suscepti-
ble to confounding and reverse causality.
Mendelian randomization (MR) is an epidemiologic technique that
utilizes genetic variants that are reliably associated with potentially modi-
fiable risk factors to determine their causal role for disease risk.13,14 MR
studies are less vulnerable to confounding, reverse causation bias and
measurement error compared with conventional observational studies.
We used the MR design to investigate the associations of short- and
long-sleep duration with overall cancer and 22 site-specific cancers.
2 | MATERIALS AND METHODS
2.1 | Study population
This MR study is based on data from the UK Biobank study.15 This
cohort enrolled around 500 000 adults, aged 37 to 73 years, from
22 assessment centers across the United Kingdom during 2006 and
2010. For this analysis, we limited the study population to individuals
of European descent to reduce population stratification bias. After
exclusion of related individuals (third-degree relatives or closer), low
genotype call rate (three or more standard deviations from the mean)
and excess heterozygosity, 367 586 participants remained for analy-
sis. The cancer outcomes were defined based on diagnosis codes, his-
tology, self-reported data (validated by interview with a trained nurse)
and follow-up information until March 2017 was used. Logistic
regression with adjustment for age, sex, genotyping array and
50 genetic principal components was used to obtain the genetic-
cancer association estimates. The analyses were conducted under UK
Biobank application 29 202. A replication analysis was performed
using data from the FinnGen consortium (R3 data release; up to
121 579 individuals). Detailed description of the methods used by
FinnGen can be found in its webpage (https://www.finngen.fi/fi).
2.2 | Instrumental variable selection
We selected all single-nucleotide polymorphisms (SNPs) previously
shown to be associated with the sleep duration traits at the level of
genome-wide significance (P < 5 × 10−8) among 446 118 UK Biobank
participants of European ancestry.16 Genetic association analysis in
this study was performed in subjects of European ancestry using
BOLT-LMM (linear mixed models) and an additive genetic model
adjusted for age, sex, 10 principal components of ancestry,
genotyping array and genetic correlation matrix.16 Linkage
What's new?
With the exception of breast cancer, the impact of sleep
duration on site-specific cancer risk remains largely
unknown. Here, using Mendelian randomization analysis, the
authors investigated the causal role of sleep duration for
overall cancer and for 22 site-specific cancers in more than
367 000 UK Biobank participants. Suggestive associations
were detected between certain cancer sites and genetic lia-
bility to short or long sleep duration or genetically predicted
sleep duration. However, no statistically significant associa-
tions were identified between sleep duration and overall or
site-specific cancer risk, indicating that sleep duration does
not have a causal influence on cancer.
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disequilibrium (defined as r2 > 0.1 in European populations) between
SNPs was evaluated using LDlink.17 Given that the association
between sleep duration and cancer risk may be nonlinear, we used
SNPs associated with continuous sleep duration as well as with short
and long sleep. The number of SNPs used were 27 for short-sleep
duration (n = 106 192 cases with <7 hours of sleep relative to
305 742 controls with 7-8 hours of sleep), eight for long sleep
(n = 34 184 cases with ≥9 hours of sleep) and 77 SNPs for continuous
sleep duration. The continuous sleep duration trait has a genome-
wide genetic correlation with both short-sleep (rg = −0.89) and long-
sleep (rg = 0.68) duration; the corresponding correlation between
short sleep and long sleep is modest (rg = −0.28).16 All instrumental
variables for each trait were harmonized so that the effect alleles
reflected the allele associated with an increased probability or level of
exposure. Details of the SNPs used as instrumental variables and their
associations with cancer are available in Supplementary Table 1.
2.3 | Statistical analyses
The analyses were performed using the mrrobust18 package in Stata (ver-
sion 14.2; StataCorp, College Station, Texas), and all statistical tests were
two-sided. The random-effects inverse-variance weighted (IVW) method
was used in the main analyses. Ratio estimates were calculated for each
SNP as the beta coefficient for the SNP-cancer association divided by the
beta coefficient for the SNP-sleep duration trait association. These esti-
mates were then combined across SNPs in a random-effects IVW meta-
analysis. The IVW method provides the highest precision but does not
correct for pleiotropic bias if present.19 For possible associations (P value
<.05, IVW method), sensitivity analyses using the weighted median and
MR-Egger approaches were conducted.19 The weighted median method
provides consistent estimates if at least 50% of the weight in the analysis
comes from valid instrumental variables.19 The MR-Egger approach can
detect and adjust for directional pleiotropy but suffers from low power.19
Additionally, we conducted a sensitivity analysis omitting sleep-
related SNPs in the FTO gene (one SNP for the long sleep duration
trait and another SNP for the continuous sleep duration trait), which
has pleiotropic effects with, for example, body mass index. In a sepa-
rate multivariable analysis, we additionally adjusted for smoking initia-
tion, that is, the obtained estimates represent the direct effect of
sleep duration, which is not driven by smoking initiation. Summary
statistics for data for smoking initiation were obtained from the publi-
shed GWAS.20 In the recent MR study on the link between sleep traits
and risk of breast cancer in UK Biobank population, no association
between the sleep trait duration allele scores and other confounding
factors (eg, physical activity and alcohol consumption) was
observed.21 As the genetic associations with sleep duration and can-
cer were assessed in the same population, the overestimation of
genetic effect sizes (winner's course bias) may occur. In the replication
stage, we performed two-sample MR analyses of associations found
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in the IVW models based on UK Biobank, using an independent
GWAS dataset from the FinnGen consortium.
Reported odds ratios (OR) with their 95% confidence intervals (CI) are
per genetically predicted one-unit increase in log odds of short- and long-
sleep duration and per genetically predicted additional hour of sleep in
every 24 hours. The Benjamini-Hochberg method was applied in the main
analysis based on the UK Biobank data to correct for multiple testing of all
69 associations. P values that passed a critical value corresponding to false
discovery rate (FDR) of .05 were considered as strong evidence of associa-
tions. P values that did not pass a critical value but were less than .05 were
considered as suggestive evidence of associations.
3 | RESULTS
There was no statistically significant association of genetic liability with
short- or long-sleep duration (Figures 1 and 2) or genetically predicted
sleep duration (Supplementary Figure 1) with overall or any site-specific
cancer after correcting for multiple testing. However, there were sug-
gestive associations of genetic liability to short sleep duration with
higher odds of cancers of the stomach (OR, 2.22; 95% CI, 1.15-4.30;
P = .018), pancreas (OR, 2.18; 95% CI, 1.32-3.62; P = .002) and color-
ectum (OR, 1.48; 95% CI, 1.12-1.95; P = .006), but with lower odds of
multiple myeloma (OR, 0.47; 95% CI, 0.22-0.99; P = .047). Genetic lia-
bility to long-sleep duration was associated with lower odds of
pancreatic cancer (OR, 0.44; 95% CI, 0.25-0.79; P = .005) and kidney
cancer (OR, 0.44; 95% CI, 0.21-0.90; P = .025) and with higher odds of
testicular cancer (OR, 2.17; 95% CI, 1.02-4.61; P = .043). Genetically
predicted continuous sleep duration showed a suggestive inverse asso-
ciation with kidney cancer (OR, 0.50; 95% CI, 0.25-0.99; P = .046).
Removing the SNP in the FTO gene did not alter the observed associa-
tions except for testicular cancer (Supplementary Table 2). Likewise,
the associations remained essentially the same after adjustment for
smoking (Supplementary Table 2). The weighted median analysis
showed similar but less precise estimates, and no directional pleiotropy
was detected in the MR-Egger analysis for most observed associations
except testicular cancer (Supplementary Table 2).
Replication analyses based on the FinnGen consortium did not reveal
significant associations of sleep duration traits with any cancer site from
the discovery stage (Supplementary Table 3). The associations of geneti-
cally predicted short sleep with colorectal cancer (OR, 1.24; 95% CI, 0.76-
2.04; P = .388) and long sleep with pancreatic cancer (OR, 0.57; 95% CI,
0.17-1.88; P = .354) were in the same direction as in UK Biobank.
4 | DISCUSSION
This MR study showed suggestive evidence of a causal associa-
tion between both short- and long-sleep duration and risk of some
site-specific cancers but not overall cancer. After applying a multiple
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testing correction, genetic liability to short sleep duration was linked
to nonsignificantly higher odds of several gastrointestinal cancers,
including stomach, pancreatic and colorectal cancers, but with lower
odds of multiple myeloma. Genetic liability to long sleep duration was
associated with nonsignificantly lower odds of pancreatic and kidney
cancers.
To the best of our knowledge, no previous MR study has inves-
tigated the association between genetically predicted short- and
long-sleep duration with overall cancer or various cancer sites. Epide-
miological studies of associations of sleep duration and risk of site-
specific cancers, other than breast cancer, are scarce and inconsistent.3
A recent meta-analysis of 25 observational cohort and case-control
studies indicated that neither short-sleep nor long-sleep duration was
associated with overall cancer risk.3 However, long-sleep (vs normal
sleep) duration was associated with an increased risk of colorectal can-
cer based on six studies (OR 1.21; 95% CI 1.08-1.34).3 It should be
noted that there was substantial heterogeneity in this meta-analysis.3
The discrepancy in results could be explained by a low number of site-
specific cancer cases in some studies, reverse causation bias, residual
confounding or reporting bias. In addition, the definition of short- and
long-sleep duration varied among studies.
Our findings for short-sleep duration and gastrointestinal cancers
partly support the results from a recent prospective study of 297 185
adults that observed an increased risk of stomach cancer in men (haz-
ard ratio 1.29; 95% CI 1.05-1.59; 409 cases among 173 327 men)
who reported sleep duration of 5 to 6 hours per night compared with
those who slept 7 to 8 hours.8 In addition, our findings are in agree-
ment with those of a case-control study involving 1240 participants
undergoing routine screening colonoscopy, which showed that short
sleep duration was associated with higher odds of colorectal ade-
noma.22 In another study, comprising 75 828 postmenopausal women
(851 incident cases), short (≤5 hours) and long (≥9 hours) sleep dura-
tion was associated with 36% and 47% increased risk of colorectal
cancer, respectively, suggesting a U-shaped association.5
In contrast to several prospective studies,5,23 we did not find evi-
dence for an adverse effect of long-sleep duration on risk of cancer. If
anything, a protective effect of long-sleep duration on kidney and
pancreatic cancers was observed.
There are several potential pathways that can explain the role of sleep
in cancer development. Sleep duration may be a surrogate for exposure to
light at night and be closely related to melatonin production, a hormone
mainly produced by the pineal gland primarily during darkness. Experimen-
tal evidence suggests that besides the important role of melatonin in regu-
lation of circadian rhythms, it is also involved in inhibition of tumor
development of a wide variety of cancers, including stomach,24 colon25
and pancreatic cancers.26 Furthermore, melatonin exhibits anti-inflamma-
tory, antiangiogenic and antioxidant properties and may promote DNA
repair.4,24,27 Due to its anticancer properties, melatonin has been proposed
as a potential candidate for the prevention and treatment of cancer.27
Another potential pathway of the relationship between short sleep
and gastrointestinal cancers is that excessive body weight, insulin resis-
tance, type 2 diabetes, altered gut microbiota, inflammation and
impaired immune function may mediate this association. For instance,
several experimental studies have demonstrated that acute sleep depri-
vation may cause an alteration in glucose and insulin metabolism28 and
hormones involved in appetite regulation, such as increased ghrelin
levels (hormone produced by the gastrointestinal tract) and decreased
leptin levels.29 Furthermore, sleep restriction was shown to increase
caloric intake and unhealthy food choices30 as well as to alter gut micro-
biota.31 These findings are consistent with epidemiological evidence
linking insufficient sleep with increased risk of obesity and type
2 diabetes,32,33 which are associated with carcinogenesis. Moreover,
sleep deprivation may indirectly, via insulin metabolism, affect circulat-
ing levels of insulin-like growth factor-1, which were positively associ-
ated with colorectal cancer in a previous MR study.34 Additionally,
recent evidence suggests that sleep deprivation and sleep disorders may
lead to decreased concentrations of the circulating anti-aging protein
Klotho,35,36 which is a tumor suppressor and modulator of insulin-like
growth factor-1 and other oncogenic signaling pathways.37Alterations
in normal sleep patterns are further linked to gastrointestinal diseases
such as gastroesophageal reflux disease, inflammatory bowel disease
and ulcer,38 which may predispose an individual to the development of
gastrointestinal cancer. With regard to multiple myeloma, its risk factor
obesity is associated with sleep apnoea and chronic intermittent hyp-
oxia, which has been recognized as a promoter of multiple myeloma.39
Shorter sleep duration in these settings may reduce the period of time
spent under a chronic intermittent hypoxic state each night and may
thus be protective for multiple myeloma risk.
A strength of this study is the MR design, which reduces con-
founding and reverse causality. In addition, we could assess the associa-
tion between sleep duration and overall cancer in a large cohort,
thereby providing high power to detect a weak association. The restric-
tion of the population to European-descent individuals minimized strati-
fication bias. A limitation of this study is that the precision of the results
was low or modest in analyses of site-specific cancers and we are unable
to discount the role of chance underlying these findings. Both the sleep-
related traits and cancer outcomes were assessed in a single population
(UK Biobank), which might have resulted in bias toward the direction of
the observational association between sleep duration and cancer. We
could not replicate the results using the FinnGen data. This disparity in
results could potentially be related to overestimation of the associations
in UK Biobank or the smaller number of cases in FinnGen. In addition,
due to a genome-wide genetic correlation of three sleep traits used in
the MR, there is an overlap in variants between these genetic instru-
mental variables16 which may increase the likelihood of chance findings.
Thus, our results require confirmation by other large MR studies.
In conclusion, this MR study does not provide strong evidence to
support causal associations of sleep duration with risk of overall and
site-specific cancers. The suggestive associations of short- or long-
sleep duration with certain cancers merit further investigation in other
large MR studies.
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